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Abstract 
 
Background: Pharmacologic treatments for type 2 diabetes are based upon increasing insulin availability and improving 
sensitivity to insulin. Nowadays, glucagon like peptide-1 (GLP-1) based therapies aims at glucose control through DPP-4 
inhibitors. DPP-4 is a transmembrane glycoprotein belongs to prolyl oligopeptidase family, with the specificity of removing 
X-Pro or X-Ala dipeptides from the N-terminus of polypeptides. GLP-1 effect by stimulating glucose-dependent insulin 
release from the pancreatic islets, inhibit inappropriate post-meal glucagon release and slow gastric emptying promoting 
leaky gut. The current study investigated DPP-4 inhibitory activity of catechin, isolated from Withania somnifera (WS), for 
ethnopharmacological treatment of type 2 diabetes and aimed to increase availability of GLP-1and sensitivity to insulin. 
Materials and Methods: Young and matured fresh roots, leaves, and fruits of WS plant extract were considered and were 
systematically evaluated for DPP-4 inhibitory activity using in vitro method, enzyme kinetics, phytochemical analysis, RP-
HPLC, LCMS and 
1
H and 
13
C NMR method and structure-activity relationship (SAR) studies. 
Results: In this study, methanol (100% and 80%) extracts of WS matured root exhibited maximum DPP-4 inhibitory 
activity when compared to other extracts. The maximum DPP-4 inhibitory activity was found in 100% methanol extract of 
matured root. Phytobioactive was purified by RP-HPLC. The compound purified was found to be flavonoid and was 
characterized (LCMS, 
1
H and 
13
C NMR studies), identified as catechin. Auxiliary, molecular docking was performed using 
Ligand Fit method using PatchDock package. The study revealed the binding affinity of catechin with DPP-4 to be -6.601 
kcal/mol with 13 hydrogen interactions with the receptor and was very similar to the standard potent blockers withaferin A 
and others (cuscohygrine, scopoletin, sitoindoside IV, tropine), further confirming its hyperglycemic potency. 
Conclusion: The study reveals that, 100% methanol extract of WS matured roots contains the compound- catechin, which 
exhibits DPP-4 inhibitory activity resulting in increased level of bioactive GLP-1 and GIP. In this background, we 
concluded that the WS will be a better source for further development as new antidiabetic drugs.  
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Introduction 
 
Withania somnifera (L.) Dunal is a small, erect, evergreen woody under shrub, which belongs to Solanaceae 
family, it is a xerophytic plant that grows up to 30-150 cm in height. This plant grows in all dry parts of subtropical India, 
such as Karnataka, Rajasthan, Punjab, Gujarat Madhya Pradesh and Uttar Pradesh. Globally, it is also found in Congo, 
South Africa, Egypt, Morocco, Jordan, Pakistan and Afghanistan (Uddin et al., 2012). The fleshy roots when dry are 
cylindrical, gradually tapering down with a brownish white surface. Leaves are simple, ovate, glabrous, 10 cm long, dense 
beneath and sparse above. Flowers inconspicuous, greenish or lubrid-yellow, in axillary, umbellate cymes; berries small, 
globose, orange-red when mature, enclosed in the persistent calyx; seed yellow, reniform (Mirjalili et al., 2009). The 
species' name somnifera means "sleep-bearing" in Latin, indicating that Ashvagandha was considered a sedative (Barnett et 
al., 2006). However, it has also been used for sexual vitality and as an adaptogen (Mishra et al., 2000). In the traditional 
system of Ayurvedic medicine, this plant is claimed to have potent aphrodisiac rejuvenative and useful in the treatment of 
antiinflammatory, antitumour, antistress, antidiabetic, antiageing, stimulant for neurotransmitter and life prolonging 
properties (Sharma et al., 2011). The dried powder of the roots, leaves and berries of Withania somnifera (WS) contains 
phytoactives such as an alkaloids, steroidal lactones, flavonoids, tannin, saponins, somniferin etc. At present, more than 12 
alkaloids, 40 withanolides, and several sitoindosides have been isolated and reported from Withania somnifera plant 
(Kulkarni and Dhir, 2008; Tursunova et al., 1977; Matsuda et al., 2001). Withaferin-A is the most important alkaloid and 
Withanolide D, steroidal lactone isolated so far from the leaves of WS and high catechin concentration detected in Withania 
somnifera have been reported
 
(Mirjalili et al., 2009; Tiwari et al., 2014; Alam et al., 2011).  
Type 2 diabetes mellitus (T2DM) or non-insulin-dependent diabetes mellitus (NIDDM) is possibly the world’s 
foremost metabolic disorder that results from defects in insulin secretion on one side and insulin resistance on the other side 
of the β-cell (Tripathy  et al., 2010). Hyperglycemia is mainly observed in people with increased concentration of 
carbohydrates and fats in their body; assisted with low physical activities (Anwer et al., 2008). Recently, considerable 
interest has been generated by a novel class of antihyperglycemic agents that act at distinct levels of the incretin therapies. 
The incretin therapies focus on the increasing levels of the two incretin hormones, glucagon like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP). Incretin hormones increase insulin secretion and they are the key 
modulators of pancreatic islet hormone secretion and regulate glucose homeostasis
 
(Pratley and Salsali, 2007). GLP-1, 
derived from the L-cells of the distal small intestine and large bowel, and GIP, derived from the K-cells of the proximal 
small intestine
 
(Dhananjayan et al., 2013). GLP-1 has direct effects on the endocrine pancreas, heart, stomach and brain and 
indirect effects on the liver and muscle (Drucker, 2006). Dipeptidyl peptidase-4 (DPP-4) (EC 3.4.14.5) or Cluster of 
differentiation 26 (CD26) is a cell-surface protease belonging to the prolyloligopeptidase family, it was first reported in 
1966 and is essential for the control of GLP-1 bioactivity and glucose balance. It is expressed on a specific set of T-
lymphocytes, where it is up-regulated after activation and also expressed in a variety of tissues, primarily on endothelial 
and epithelial cells
 
(Lambert and Yang, 2003). GLP-1 is a 30-amino acid polypeptide that promotes blood glucose 
homeostasis by stimulating insulin secretion from pancreatic β-cells in a glucose-dependent manner. DPP-4 cleaves GLP-1 
at the N-terminal end to release a dipeptide, thereby converting active GLP-1 (7-36 amide) to inactive GLP-1 (19-36 
amide). Hence DPP-4 has emerged as a validated and biotarget for type 2 diabetes mellitus. An inhibitor of DPP-4 is likely 
to lower blood sugar levels by increasing the level of active GLP-1
 
(Joseph et al., 2009). The DPP-4 inhibitors enhance the 
body's own ability to control blood glucose by increasing the active levels of incretin hormones in the body. Their 
mechanism of action is distinct from the existing class of oral glucose-lowering agents. They control elevated blood glucose 
by triggering pancreatic insulin secretion, suppressing pancreatic glucagon secretion, and signaling the liver to reduce 
glucose production
 
(Deacon, 2011). 
In recent years, in silico modeling has become an important tool for drug designing. Virtual screening and 
molecular docking studies are of high priority in drug discovery and development (Lakshmi Ranganatha et al., 2013). Most 
of the molecular docking algorithms assume the enzyme as rigid object which leads to inappropriate correlation of the 
docking scores. There is no single docking algorithm or scoring function that can correctly predict the binding affinities of 
ligand in molecular interaction. For these reasons, in the present study, a highly validated docking program such as Ligand 
Fit method in Patch Dock software package was used to investigate and identify the interaction of ligand molecule in the 
active region of the protein and to predict the binding affinity between the ligand and the receptor protein molecules using 
atomic contact energy (ACE) or glide values (Madhusudan et al., 2016). 
The pharmacological DPP-4 inhibitors as therapy of T2DM to attain adequate glycemic control is firmly 
established and numerous inhibitors are in varying stages of clinical development (Brown and Evans, 2012). The current 
DPP-4 inhibitors available are saxagliptin, sitagliptin, alogliptin and vildagliptin. Validagliptin is licensed in Europe and 
Latin America in 2007, alogliptin is licensed only in Japan in 2010
 
(Deacon, 2011; Brown and Evans, 2012; Verspohl, 
2009). At the same time so many studies investigated adverse effect of current DPP-4 inhibitors were causes 
nasopharyngitis, upper respiratory tract infection, urinary tract infection, serious allergic reactions, headache, anaphylaxis, 
angioedema, Nausea, diarrhea and abdominal pain and low blood sugar levels specially when taken in over dosage
 
(Chakrabarti et al., 2011; Idris and Donnelly, 2007; Pathak et al., 2010).But herbal products doesn’t cause any side effects,  
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our products is herbal.  In the present study, different solvent extract of WS were studied for DPP-4 inhibitory activity and 
followed by isolation and characterization of the active compound, catechin. This study is the first report on catechin 
exhibiting the strong inhibition of DPP-4, which strongly supports the possible potential for the incretin, based antidiabetic 
therapy. 
 
Materials and Methods 
Chemical reagents  
 
Gly-pro-p-nitroanilide [GPPN], Diprotin-A [Ile-Pro-Ile], Porcine kidney DPP-4, Tris-HCl buffer and solvents used 
for extraction and purification were purchased from Sigma-Aldrich. All other chemicals were of analytical grade. 
 
Plant materials 
 
Young and matured fresh roots, leaves and fruits of WS plant were collected from Kestur Koppal village of 
Krishna Raja Nagar Taluk in Mysore District, Karnataka State, India [co-ordinate - 12.46°N 76.39°E] in the month of 
August and September 2013 to 2014. It was identified and authenticated by competent botanist Dr. Rajakumar H. 
Garampalli with voucher specimen number PK2013. The herbarium of the same was deposited in the Department of studies 
in Botany, University of Mysore, Mysore and Karnataka, India. All samples were processed as per the schema shown in 
Fig.1. 
 
 
                                          
Figure 1: Schematics of the work flow. 
 
WS plant methanol extract 
 
The collected root, leaf and fruit parts of the plant was brought into the laboratory, cleaned, shade dried and then 
ground into fine powder. About 200 g of root, 70 g of leaf and 25 g of fruit dry powder of matured and young plant of WS 
was extracted with 80% and 100% methanol, at 70°C by continuous hot percolation using a Soxhlet apparatus. The 
extraction was continued for 24 hrs and then extract were filtered and kept in oven at 40°C for 24 hrs to evaporate the 
solvents moisture. The concentrated extract was dissolved in minimal amount of water and washed three times with 
chloroform. The residual layer was extracted three thrice with ethyl acetate. All the extracts are finally pooled and 
concentrated using the rotator evaporator. The yield of 100% and 80% methanol extracts from matured and young root, leaf 
and fruit extract were collected then labelled specifically and kept separately in air tight containers in a deep freezer until 
the time of use for the screening of enzyme inhibitory activity and further studies
 
(Rahman, 2013; Tomsone et al., 2012; 
Sinha, 2012). 
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WS plant Buffers and saline extract 
  
About 200 g of root, 70 g of leaf and 25 g dry powder of matured and young plant of WS was cold macerated with 
1% saline solution, phosphate buffer (0.2 M, pH 7.4) and acetate buffer (0.2 M, pH 4.5) with intermittent shaking at 2 hrs 
intervals for 72 hrs. The filtrate obtained was concentrated using rotator evaporator. A highly non-polar solvent such as 
hexane was used to remove the chlorophyll and pigments out of the extract. The extract was then centrifuged with 10,000 
rpm for about an hour and concentrated supernatant were transferred to a clean vial. The yield of 1% saline solution, 
phosphate buffer (0.2 M, pH 7.4) and acetate buffer (0.2 M, pH 4.5) extracts from matured and young root, leaf and fruit 
extract were collected then labelled specifically and kept separately in air tight containers in a deep freezer until the time of 
use for the screening of enzyme inhibitory activity and further studies
 
(Rahman, 2013; Tomsone et al., 2012; Sinha, 2012). 
 
DPP-4 assay 
   
 The in vitro inhibition of DPP-4 was assayed as described by Kojima et al. (1980) method. The substrate was 
cleaved by the enzyme serine aminopeptidase DPP-IV resulted the release of paranitroaniline (pNA), a yellow coloured 
product which was measured at 410 nm. The varied concentration of plant extract (5, 25 and 125 µg/mL) and Diprotin-A as 
standard inhibitor in 1 mL of Tris-HCl buffer (pH 8.4) was pre-incubated with 50 µL of DPP-4 (0.05 U/mL) enzyme for 30 
min at 37 
º
C.  After pre-incubation, 60 µL of 10 mM gly-pro-p-nitronilide was added and the final reaction mixture was 
made up to 1.5 mL using Tris-HCl buffer (pH 8.4) and then incubated at 37 
º
C for 30 min and absorbance was finally read 
at 410 nm. One  unit  of enzyme  activity  was  defined  as  the amount  of  enzyme  that  catalyzes  the  release  of  1 µmol 
of p-nitroniline from the substrate/min under assay conditions
 
(Baetta and Corsini, 2011; Kojima et al., 1980; Yogisha and 
Raveesha, 2010).  
 
Statistics 
 
Data were expressed as the mean ± S.E.M. For statistical analysis of the data, percentage of inhibition was calculated using 
the following formula:  
                                  Absorbance of control  - Absorbance of inhibitor 
Percentage Inhibition  =                                                                                                      X 100 
                    Absorbance of control 
 
Determination substrate Km value 
 
Determination of the Km value (Michaelis-Menten) for gly-pro-p-nitronilide (0.5 to 400 μM) as per the method of 
Liu et al., 2012. Before adding the substrate, 1 mL of Tris-HCl buffer (pH 8.4) was pre-incubated with 50 µL of DPP-4 
(0.05 U/mL) enzyme for 30 min at 37 
º
C. After incubation the reaction was initiated by addition of various concentration of 
substrate finally read at 410 nm. The reaction mixture without enzyme was used as blank. The substrate concentration 
values was analyzed in GraphPhad prism nonlinear regression curve fit through the link of enzyme kinetics. From the 
Michaelis-Menten equation we determined the Km and Vmax of enzyme with different parameters. 
 
Using equation for Km value calculation: Y = Vmax*X / (Km+X) 
 
Where ‘X’, ‘Y’, ‘Vmax’ and ‘Km’ are substrate concentration, intial velocity, maximum velocity, Michaelis-Menten 
constant respectively. 
 
Determination of Ki value 
 
Determination of the Ki value (Competitive inhibition) the concentrations of gly-pro-p-nitronilide varied from 0.5 
to 800 μM as per the method of Xiao et al., 2016. In the investigation was in the absence or presence of WS methanolic 
extracts at various concentrations (0.1–125.0 μM/mL). Dissolved in in Tris-HCl buffer (pH 8.4) and follow the methods of 
above DPP-4 assay with various concentration of substrate gly-pro-p-nitronilide from 0.5 to 800 μM the reaction was 
initiated by addition of enzyme and the reaction measured at 410 nm. The absorbance and various concentrations of  
substrate was analysed in GraphPhad prism nonlinear regreation curve fit through the link of enzyme kinetics and 
competitive inhibition using below equation to the determined Ki, Km and Vmax of enzyme with best fit values. 
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Using equation for calculation of Ki value: 
 
                             KmObs = Km (1+[I]/Ki)   and    Y=Vmax*X/(KmObs+X) 
 
‘X’, ‘Y’, ‘Vmax’, ‘Km’, ‘Ki’ and ‘I’ are substrate concentration, enzyme velocity, maximum velocity, Michaelis-Menten 
constant, inhibition constant and inhibition concentration respectively. 
 
Fractionation of extracts by HPLC  
 
Based on screening different parts of the WS extract for inhibition of DPP-4, 100% methanolic root extract has 
shown the highest inhibition. Hence this extract was (5 mL) was injected into the HPLC C-18 column (SHIM-PACK, 
2.2×25 cm, particle size 10 μm and pore size 30 nm), attached to a LC-8A, Shimadzu HPLC system (Shimadzu Asia 
Pacific Pvt. Ltd, Singapore), was done at 37 
º
C using solvent A as triple distilled water with 0.1% tri-fluroaceticacid and 
solvent B as methanol with 0.1% tri-fluroacetic acid. Flow rate was maintained at 7 mL/min and run time was 45 min. The 
eluted sample observed at different wavelength and chromatogram was recorded
 
(Khoddami et al., 2013; Rajasekar and 
Elango, 2011; Ghafoor et al., 2012; Dalavayi et al., 2006). The peak area of eluted samples was collected in different 
fraction and was used to determine DPP-4 inhibitor activity as per the Kojima et al., (1980) method. 
 
Phytochemical analysis 
 
The fractions from HPLC column were analyzed for  phytochemicals by qualitatively for the identification of 
active compounds namely  alkoloids, terpenoids, flavonoids, proteins, tannins and saponins by Drogendroff’s test, 
Salkowski test, aluminum chloride test, Million’s test, lead sub acetate Test and Frothin  test respectively.  
 
Shinoda's test for flavonoids 
 
About 0.5 mL of each sample was dissolved in ethanol, warmed and then filtered. Three pieces of magnesium 
chips was then added to the filtrate followed by few drops of Conc. HCl. A red to purple colouration indicates the presence 
of flavonoids was analysis as per the Usman et al., 2009; Trease and Evans 2002. 
 
Ferric chloride test for flavonoids 
 
About 0.5 mL of each sample was boiled with distilled water and then filtered. To 2 mL of the filtrate, few drops 
of 10% ferric chloride solution were then added. A violet coloration indicated the presence of a phenolic hydroxyl group 
was analysis as per the Usman et al., 2009; Trease and Evans 2002. 
 
RP-HPLC with standard flavonoids compound 
 
The HPLC fraction peak which confirmed positive results of flavonoid from phytochemical analysis and showed 
maximum inhibitory activity  was used for further purification process by preparative HPLC followed by the above 
procedure and on the other hand, standard flavonoids compound (Gallic acid, Gentisic acid, Catechin, Caffeic acid, 
Epicatechin, p-Coumaric acid, Myricetin, Quercetin) were also injected, System was done at 30
°
C using solvent A as triple 
distilled water with 0.1% tri-fluroaceticacid and solvent B as methanol with 0.1% tri-fluroaceticacid, flow rate was 
maintained 7 mL/min and  run time was 45 min. The eluted sample observed at different wavelength and chromatogram 
was recorded
 
(Alam et al., 2011; Dalavayi et al., 2006). The peak area of the eluted samples collected in different fraction 
and used to determine DPP-4 inhibitor activity as per the Kojima et al., (1980) method. 
 
Mass spectrophotometer  
 
All electrospray ionization experiments were performed using a QSTAR XL hybrid mass spectrometer (AB/MDS 
Sciex) hyphenated with microscale capillary reversed-phase HPLC (Famous autosampler (LC Packings), Agilent 1100 
HPLC pump (Agilent). The columns were packed in-house using Magic C-18 (5_m, 200 Å, Michrom BioResources) beads. 
The solvent compositions are as follows: by methanol with 0.1% tri-fluroaceticacid and water with 0.1% tri-fluroaceticacid. 
For the quantitation experiments a 5 min gradient was used with mass spectra being acquired every 0.15sec. Data analysis 
and quantitation was done using the Analyst software package provided by Applied Biosystems/MDS Sciex. 
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1
H and 
13
C NMR spectral measurements 
 
The 
1
H and 
13
C NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer (Bruker cop. Germany) 
using TMS as internal standard and CDCl3 as solvent at ambient temperature. The NMR characterization is helpful in 
predicting the molecular structure of an isolated compound. Usually, the compound whose molecular structure needs to be 
elucidated is taken (~ 5 mg) into a clean NMR tube and dissolved using deuterated solvent (CDCl3, in this case) (Kumar et 
al., 2016). 
 
Molecular Docking 
Structure-Activity Relationship (SAR) studies: 
 
Molecular docking was performed to establish the correlation between the WS isolated and characterized catechin 
molecule (Pub chem. CID – 73160) and the top five potent inhibitors namely Cuscohygrine (Pub chem. CID – 441070), 
Scopoletin (Pub chem. CID – 5280460), Sitoindoside IV (Pub chem. CID – 127197), Tropine (Pub chem. CID – 449293) 
and Withaferin A (Pub chem. CID – 265237) respectively with that of the target DPP-4 enzyme (Accession: PDB-1nu6). 
The crystal structure were built using CPH Models server 3.0. Energy computations were performed on the molecule using 
GROMOS96 implementation of Swiss-PDB Viewer. Electrostatic point charges on the molecules were calculated. The 
ligands were docked into the active site using the Molecular Docking software PatchDock with default parameters 
(Mashiach et al., 2010). PatchDock is an algorithm for calculating the docking modes of small molecules into protein-
binding sites based on their shape complementarity. In this we have used ChemScore, a scoring function that is derived 
from regression against receptor-ligand binding free energies. The structures of the ligands for the current study were 
constructed using Dundee PRODRG Server
 
(Thomsen and Christensen, 2006) which optimizes the conformation of the side 
chains and minimizes the energy. The minimum energy conformers of ligands were interactively docked into close 
proximity with the enzyme active site pocket. The possibility of binding, precise location of binding sites and the mode of 
ligand binding was carried out using automated MolDock software, which is based on guided differential evolution and a 
force field-based screening function (SchuÈttelkopf and Van Aalten, 2004). Possible binding conformation and orientations 
were analyzed by clustering methods using the enzymatic model. The enzyme was visualized using sequence option. The 
binding site was computed within spacing such that the binding site was well sampled with a grid resolution of 0.3 Å. The 
ligand was docked into this grid using the Pymol Optimizer algorithm and its interactions monitored using detailed energy 
estimates. A maximum population of 100 and maximum interactions of 10,000 were used for each run and the five best 
poses were retained. The software was utilized to identify hydrogen bonds and hydrophobic interactions between residues 
at the active site and the ligand (Rakesh et al., 2016). 
 
Results 
 
Methanol [80% and 100%], 1% saline solution, 0.2 M phosphate buffer (pH 7.4) and 0.2 M acetate buffer (pH 4.5) 
extracts of the root, leaves and fruit part of the young and matured plant of WS was studied for inhibition of DPP-4 activity. 
Preliminary level of screening was performed at a concentration of 25 µg/mL of each extract for DPP-4 inhibitoty activity, 
where WS root parts showed the maximum inhibition activity compared to leaves and fruit extracts as shown in Fig. 2A 
and Fig. 2B. Based on the results the above screening samples were narrowed down to root parts for further studies. Dose 
dependent studies (5 µg/mL and 125 µg/mL) of different concentration of young and matured root extracts were performed. 
Meanwhile, inhibitory activity for leaves and fruits extract were less significant than compared to the root extract. 
Henceforth, root extracts were subjected for further studies. The 100% and 80% methanolic extract of matured roots of WS 
shown 86.0 ± 0.61% and 81.9 ± 0.0 6% inhibition of DPP-4 respectively at 125 µg/mL. The methanol extract macerated 
with 1% saline solution, phosphate buffer and acetate buffer showed  70.4 ± 0.72%,   80.3 ± 0.29% and  71.2 ± 1.19% of 
inhibition respectively at a concentration of 125 µg/mL in all the cases (Fig. 2B). Similar to the mature root extract, the 
100% and 80% methanol,  saline solution, phosphate and acetate buffer  extract of young root inhibited the DPP-4 activity. 
The respective inhibition percentage is shown in the (Fig. 2A). The percentage of inhibition of DPP-4 by the matured root 
extract was found to be high compared to the young root extract; hence we proceeded with 100% methanolic extract of 
matured root for the purification and characterization of active compounds present in it. The 100% and 80% methanolic 
extracts of WS matured root were showed good inhibition activity with an IC50 value of 8.76 µg/mL and 21.03 µg/mL 
respectively. Diprotin-A served as the positive control, well knew inhibitor of DPP-4. Linear regression of standard 
inhibitor of diprotin-A IC50 value was 4.1346 µg/mL and p-value was 0.0109 with significance showed in fig. 3A.  
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Figure 2: Dose dependent enzyme inhibitory activity of (A) young root and (B) mature root extracts of Withania 
somnifera. 
The Km value determination was done in GraphPad prism software nonlinear regression curve fit, enzyme kinetics and 
Michaelis-Menten by varied the concentration of the substrate Gly-Pro-pNA (0.5 mM to 400 mM) and DPP-4 enzyme 
activity graph showed in the fig.3B. Michaelis-Menten of substrate concentration results in various parameters It was found 
that "Best-fit values" the Km value was 97.70μM and Vmax value was 2.737μM. "95% Confidence Intervals" the Km value 
was 55.01 to 140.4 μM and Vmax value was 2.288 to 3.186 μM and "Goodness of Fit" the R² is 0.9885 with 6 Degree of 
Freedom. The Ki value determined by GraphPad prism software through the competitive inhibition at 5, 25 and 125 
μM/mL of plant extracts, obtained graph in fig.3C and showed the results in Best-fit values parameters. It was found that Ki 
value was "~ 4.157e+016"μM, Km & Vmax values were 221.1 μM and 2.352 μM respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(2A)          
(2B) 
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Figure 3:  (A) Standard Diprotin-A (B) Km value of substrate concentration and (C) Ki value of inhibitory concentration. 
Further, 100% methanol extract of matured root was subjected to preparative HPLC for the isolation of active principles.  
 
As revealed in the HPLC chromatogram (Fig. 4A), the matured root extract was fractionated into many peaks and 
each peak were analyzed for DPP-4 inhibitory activity.  Among all the peak fractions, the fractions which have retention 
time of 14 to 16 min exhibited DPP-4 inhibitory activity and hence these fractions were pooled and lyophilized until further 
use. The qualitative phytochemical analysis was carried out in the pooled samples obtained from HPLC chromatogram. 
Drogendroff’s test, Salkowski test, ferric Chloride test, Million’s test, Lead sub acetate test and Frothin test were carried for 
the presence of phytochemical constituents. The pooled fractions showed only positive result for Ferric chloride test and 
Shinoda’s test suggesting the presence of flavonoids.  
Further, purification and characterization was performed by HPLC followed by LCMS for the confirmation of 
flavanoids. The pooled sample from the HPLC chromatogram was further rechromatoghraphed by HPLC. There were many 
peaks in the re-chromatographed chromatogram (Fig. 4B) and the peak having the retention time 15.827 min was 
comparatively similar with the standard compound catechin, but other standard compounds like Gallic acid, Gentisic acid, 
Caffeic acid, Epicatechin, p-Coumaric acid, Myricetin, Quercetin were not matched to any other peaks. The same fraction 
was found to have maximum inhibitory activity than compared to other peaks and crude extracts. With all this bioanalytical 
background, the flavonoid compound was identified as catechin. 
 
 
 
(4A) 
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Figure 4: (A) Maximum DPP-4 inhibitor fraction was injected to C-18 column, (B) Repurification of the active fraction 
using RP-HPLC. 
 
The spectrum was recorded in the ESI +ve mode on a QSTAR XL hybrid mass spectrometer and the calculated 
mass was found to be 288.87 Da in Fig. 5A. and as the data of 
1
H and 
13
C NMR spectra shown in Fig. 5B and Fig. 5C, 
Yield: 14 mg (Creamish yellow colour ); IR (KBr): 3400, 2600, 1618, 1520, 1470, 1380, 1280, 1240, 1150, 1120, 1080, 
1020, 820 cm
-1
 UV λmax 277 and 220 nm; 
1
H-NMR (400 MHz, CDCl3) δ 7.08 (1H, d, Ar-H, J = 8 Hz), 6.93 (1H, d, Ar-H, J 
= 4 Hz), 6.79 (1H, ddd, Ar-H, J = 4 Hz), 5.61-5.43 (2H, dd, Ar-H, J = 16 Hz), 3.89 (2H, m, CH2), 2.71-2.58 (2H, dd, CH2, J 
= 16 Hz); 
13
C-NMR (100 MHz, CDCl3) δ 164.45-106.16 (Ar-C), 89.39 (C-O), 30.00 (CH2); ESI-MS: m/z cald.s 290.07 
[M)
+, found-288.87 [M  ̶1]+ (Calculated for C15H14O6). On the basis of the above results and the available spectral literature 
(Shen et al., 1993 and Poon et al., 1998), compound was identified as catechin [(2R, 3S)-2-(3, 4-dihydroxyphenyl)-3, 4-
dihydro-2H-chromene-3, 5, 7-triol]. Catechin (C15H14O6) is belongs to the family flavonoid, which is a kind of natural 
phenol belonging to the flavon-3-ols group (flavonols)
 
(Rahman, 2013; Tomsone et al., 2012). Thus we confirm that the 
active compound present in 100% methanol extract of WS matured root is Catechin. 
 
 
 
(4B) 
(5A) 
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Figure 5: (A) Mass spectrum of 100% methonolic matured root extract HPLC purified 15.827 min fraction showing its 
mass is 288.87Da, (B) 
1
H NMR spectra and (C) 
13
C NMR spectra of catechin.  
 
Further, molecular docking of DPP-4 with catechin and other potent inhibitors revealed the potency of binding is 
very much similar to Withaferin A than compared to cuscohygrine, scopoletin, sitoindoside IV and tropine respectively as 
indicated with the docking pose (Fig. 6) and their hydrogen bonding with atomic contact energy (ACE) gliding energy 
scores as indicated (Table 1) along with their respective docking domain sites. Catechin from WS was found to be a active 
inhibitor of DPP-4 protein with binding energy -6.60 kcal/mol, in total 13 hydrogen bond interactions were found however, 
among them 6 interactions were strongly bound at amino acid residues of Glu 347, Met 348, Ser 349, Thr 351, Ile 375, Asn 
377, Glu 378, Gly 380 and Asp 588. The -SH of Met and –OH of Ser are the main players in enhancing the binding affinity 
between the protein and catechin, thus leading to increased aromaticity eventually blocking the catalytic sites. However, the 
same residues were also seen in the standard inhibitor ligands respectively (Table 1).  
 
(5B) 
(5C) 
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Figure 6: Structure-Activity Relationship (SAR) and binding affinity of DPP-4 enzyme with top five potent bioactive 
compounds of WS namely (A) Cuscohygrine, (B) Scopoletin, (C) Sitoindoside IV, (D) Ttropine, (E) Withaferin A and (F) 
Catechin respectively. 
 
Table 1: Structure-Activity Relationship (SAR) and binding affinity of DPP-4 enzyme with top five potent bioactive 
compounds of WS namely cuscohygrine, scopoletin, sitoindoside IV, tropine, withaferin A and catechin respectively 
 
 
Name of the 
biomarker 
 
 
Name of the 
compound 
 
Details of H-bond interaction 
 
 
Atomic 
Contact 
Energy 
(ACE) 
values 
 
 
Glide Score 
kcal/mol 
 
 
Amino acid residues of 
docked domains No. of 
bond 
Bond 
energy 
Bond 
length 
 
 
 
 
 
 
 
 
 
 
 
 
 
DPP-4 
enzyme 
Cuscohygrine 3 -2.5 
-1.41 
2.804 
3.058 
3.317 
1.977 
 
-173.23 -3.464 Glu 347, Ser 349, Thr 
350, Thr 351, Ser 376 
Scopoletin 1 -1.307 3.035 -169.24 -3.384 Asn 74, Ile 76, Asn 92,  
Phe 95, Tyr 105 
 
Sitoindoside IV 1 -0.519 2.362 
 
-115.57 -2.111 Ile 148, Asn 150 
Tropine  7 -2.5 
-0.564 
-0.284 
 6.230 
-1.008 
 2.501 
 0.161 
3.002 
2.367 
3.543 
1.583 
3.398 
3.037 
2.281 
-147.19 -2.943 Pro 510, Ser 511, Phe 
559, Arg 560, Thr 565 
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Withaferin A 4 -0.067 
-0.211 
-5.257 
8.2906 
3.350 
3.458 
2.432 
1.346 
-339.71 -6.794
*
 Lys 71, Asn 74, Asn 92, 
Ser 93, Phe 95, Asp 96, 
Glu 97, Ile 102, Asn 103, 
Tyr 105 
 
Catechin 
 
13 -2.5 
-2.251 
-3.951 
 0.657 
-1.286 
-0.035 
-0.564 
 0.245 
-0.926 
-1.284 
-2.5 
 2.673 
-2.5 
3.012 
2.928 
2.648 
3.191 
3.342 
3.326 
3.487 
3.483 
2.411 
3.343 
2.992 
1.992 
3.099 
-328.10 -6.601
**
 Glu 347, Met 348, Ser 
349, Thr 351, Ile 375, 
Ser 376, Asn 377, Glu 
378, Gly 380, Asp588 
 
 
 
Discussion 
 
           Several studies have been carried out in the last few decades by using the various extract/chemical constituents of 
WS for its biological activity, mostly by using the non-standardized extract derived from the roots of wild plants. Several 
specific reports have evidenced the antistress, cardioprotective, antiosteoarthritis, immunomodulatory, anticancer, 
antitumour and antiageing
 
(Mirjalili et al., 2009; Sharma et al., 2011; Anwer et al., 2008) of this botonical. The current 
study aims on the incretin based anti-diabetic approach of WS extract and its purified component by assessing the inhibition 
DPP-4 activity.  
The 100% and 80% methanol, 1% saline solution, 0.2 M phosphate buffer (pH 7.4) and 0.2 M acetate buffer (pH 
4.5)  extracts of the root, leaves and fruit part of the young and matured plant of WS were studied for DPP-4  inhibitory 
activity. Among the different extract of WS, the 100% methanolic extract of matured root showed comparatively higher 
inhibition of DPP-4 activity with IC50 value was 8.76 µg/mL, Km value was 97.70 μM and Ki value was ~ 4.157e+016 μM. 
Further, the component responsible for the inhibition of DPP-4 in 100% methanolic extract of matured root was purified by 
RP-HPLC and identified as Catechin. The purified catechin was further confirmed by LCMS analysis (Fig.5A) and 
characterized by proton NMR spectrum of catechin (Fig.5B) was recorded using a 400-MHz spectrometer and CDCl3 as a 
solvent. The comprehensive data for isolated catechin are given as follows: The three doublet signals observed at δ 7.08–
6.76 ppm was due to aromatic protons. The doublet of doublets between δ 5.61-5.43 ppm was assigned to aromatic proton. 
The multiplet observed at δ 3.89 ppm was due to methylene protons and also a doublet of doublet observed between δ 2.71-
2.58 ppm due to methylene proton. This was further supported by 
13
C NMR spectrum as discussed in experimental section 
(Fig. 5C).  
Finally, In this study, catechin was identified to be very promising candidate for blocking DPP-4 protein hence to 
be very beneficial in the treatment of diabetes mellitus, which is evident from the results of In vitro and In silico models, 
together with its remarkable activity make catechin a great interest for further studies. We have shown in our previous 
report that, compounds from WS could act as novel inflammatory inhibitors with high selectivity and precision 
(Madhusudan et al., 2016). Studies are currently underway to confirm the role of this active compound(s) and to 
characterize the precise mechanism involved at a molecular level to trace the pathway of action. The accurately known 
geometries may allow us to draw some conclusions on the enzyme mechanism and suggest a possible scenario to hamper 
many life style disorders specifically diabetes. 
Present in vitro study describes the antidiabetic activity of 100% methanolic mature root extract of WS and 
Catechin. Catechin is a type of natural phenol belonging to the group of flavon-3ols, a part of the chemical family of 
flavonoids. Catechin is one of the most important polyphenols that provide health benefits is found in WS and green tea. 
Modern studies have found that catechin is responsible for antioxidant activity, antimicrobial activity, anti-ageing and anti-
diabetic properties
 
(Lambert and Yang, 2003; Liu et al., 2014). The potent antioxidant property of catechin reduces free 
radical damage to cells and prevents the oxidation of LDL, cholesterol and blood glucose level
 
(Cooper et al., 2005; Matsui 
et al., 2007). 
Several studies have reported that DPP-4 inhibitor drugs have been established to the therapy of type-2 diabetes 
mellitus. Catechin inhibition of DPP-4 enzyme activity results in increased level of bioactive GLP-1 and GIP, improved the  
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glucose tolerance, HbA1c and resistant to hyperglycaemia (Joseph et al., 2009; Deacon, 2011). Nowadays incretin therapy 
has provided a new treatment option for patients with type 2 diabetes mellitus. The incretin therapies focus on the 
increasing levels of the two incretin hormones, GLP-1 and GIP. GLP-1 and GIP are hormones secreted by the 
enteroendocrine cells of the gut in response to the ingestion of nutrients. GLP-1 is the substrate for the enzyme DPP-4. 
DPP-4 is a serum protease which degrades GLP-1 into its inactive form. DPP-4 cleavage occurs at second amino acids 
(alanine or proline) from N-terminal. The cleavage of second amino acid (alanine) of GLP-1 by DPP-4 largely inactivates 
the GLP-1 (Deacon 2004). DPP-4 inhibition can be an effective approach to treat type 2 diabetes mellitus by increasing the 
level of active GLP-1 and also potentiates insulin secretion and suppress the glucagon secreation
 
(Verspohl, 2009). DPP-4 
inhibitor also exceeds the half-life of GLP-1 from 1 min to 5 min or some extent by inhibiting DPP-4 enzyme in the body. 
This GLP-1 increase in human body activates the GLP-1 receptor in pancreatic beta cell to produce insulin and lowers the 
glucose level in human body (Golightly et al., 2012). Same has been illustrated in Fig 7. The clinical studies of type 2 
diabetes with respect to DPP-4 inhibitor were performed by so many researchers, they confirmed the above by reducing 
fasting blood glucose levels and HbA1c values. (Ahrén et al., 2002). Several researches have revealed that DPP-4 inhibitors 
as new class of anti-hyperglycemic agents. So this study demonstrates that the catechin present in WS roots could be better 
lead for development of new antidiabetic therapeutics. 
 
 
Figure 7: Schematics exhibiting the proof of concept (antidiabetics) and interaction of catechin with DPP-4 enzyme. 
 
 
Conclusion 
 
 In conclusion, WS extracts has potent DPP-4 inhibitory activity. This study reinforces the ethnopharmocological 
observation that WS could have potent antidiabetic effects. Catechin, isolated from the plant extract may have the potential 
to serve as template for the development of new generation antidiabetic drug. DPP-4 inhibitor activity, enzyme kinetics, 
phytochemical analysis and spectral studies showed strong evidence for catechin, a flavonoid has potent DPP-4 inhibitory 
activity. Our plant extract  acts as a DPP-4 inhibitor is likely to lower blood sugar levels by increasing the active levels of 
incretin hormones (GLP-1) in the body
. 
However, further work can be utilized for the in vivo and in silico method for 
determining the pharmacological and clinical parameters through the evaluation of antidiabetic activity of both WS plant 
extract and its active compound Catechin. 
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